ArticleJournal of the Chinese Medical Association : JCMA2025
Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.Targeted oncology · 2026Review
- Optimal sequencing may be very critical to prognosis during the application of multimodality treatment strategy.Journal of the Chinese Medical Association : JCMA · 2026Article
- A challenge for treating patients with extensive-stage small cell lung cancers, particularly for those with liver metastases.Journal of the Chinese Medical Association : JCMA · 2025Article
- Optimizing outcomes for the patients with extensive-stage small-cell lung cancer.Journal of the Chinese Medical Association : JCMA · 2025Article
- Is C3c structure useful as biomarkers for epithelial ovarian cancer?Journal of the Chinese Medical Association : JCMA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited information is available regarding the clinical features and outcomes of advanced human epidermal growth factor receptor 2 ( HER2 )-mutant non-small cell lung cancer (NSCLC) in Taiwan, despite expanding treatment options for this distinct subtype. This study aimed to investigate the clinical characteristics and outcomes of HER2-mutant NSCLC in a real-world setting.
methodsRelevant data were collected from patients with advanced or recurrent HER2 -mutant NSCLC who received systemic therapy between 2011 and 2021 and were followed up until 2022 at two medical centers in Taiwan. Clinical features, treatment responses, and survival-related factors were analyzed.
resultsThis study included 45 patients (median age: 59.7 [range: 41.3-78.7] years). A775_G776insYVMA was the most common HER2 mutation subtype (57.8%), followed by G778_P780dup (11.1%). Approximately 53.3% of the patients received first-line platinum-based chemotherapy (PC) alone, whereas 13.3% received PC combined with an immune checkpoint inhibitor (ICI). The median overall survival (OS) and progression-free survival (PFS) after first-line therapy were 25.8 and 4.4 months, respectively. The objective response rate was generally higher in patients receiving first-line PC + ICI than those receiving PC alone (33.3% vs 12.5%; p = 0.269). Furthermore, patients receiving PC + ICI had longer PFS than those receiving PC alone (9.5 vs 4.4 months; p = 0.131) and those receiving tyrosine kinase inhibitor/ICI monotherapy (9.5 vs 0.5 months; p = 0.015). Compared with patients having other NSCLC subtypes, those carrying HER2 exon 20 insertion mutations had shorter median PFS (17.3 vs 2.9 months; p = 0.043) and OS (not reached vs 19 months; p = 0.031).
conclusionThis study highlights the clinical features and outcomes of advanced HER2 -mutant NSCLC in Taiwan. PC + ICI may be more effective than other regimens as first-line therapy. The prognostic impact of HER2 exon 20 insertion mutations warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.